Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Assets (2016 - 2025)

Historic Assets for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $396.1 million.

  • Ironwood Pharmaceuticals' Assets rose 167.98% to $396.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.1 million, marking a year-over-year increase of 167.98%. This contributed to the annual value of $350.9 million for FY2024, which is 2550.88% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Assets of $396.1 million as of Q3 2025, which was up 167.98% from $342.9 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Assets ranged from a high of $1.2 billion in Q1 2023 and a low of $327.2 million during Q1 2025
  • For the 5-year period, Ironwood Pharmaceuticals' Assets averaged around $705.7 million, with its median value being $599.3 million (2021).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Assets soared by 12708.72% in 2021 and then tumbled by 6201.61% in 2024.
  • Ironwood Pharmaceuticals' Assets (Quarter) stood at $1.1 billion in 2021, then decreased by 2.34% to $1.1 billion in 2022, then tumbled by 57.2% to $471.1 million in 2023, then fell by 25.51% to $350.9 million in 2024, then grew by 12.87% to $396.1 million in 2025.
  • Its last three reported values are $396.1 million in Q3 2025, $342.9 million for Q2 2025, and $327.2 million during Q1 2025.